| Indication | Advanced renal cell carcinoma with a clear cell component (ccRCC) following treatment with an anti-PD-1/PD-L1 therapy |
| Drug | Belzutifan and Lenvatinib |
| Mechanism of Action | HIF-2α inhibitor and multi-targeted VEGFR-TKI |
| Company | Merck |
| Trial Phase | Phase 3 |
| Trial Acronym | LITESPARK-011 |
| NCT ID | NCT04586231 |
| Category | Regulatory Milestone |
| Sub Category | Approval Pending |
| Therapeutic Area | Oncology |
| Regulatory Body | European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) |
| Regulatory Outcome | Positive Opinion |
| Potential Approved Region | European Union, Iceland, Liechtenstein, Norway |
| Comparator Drug | Cabozantinib |
| PFS Risk Reduction | 26% (HR=0.74 [95% CI, 0.61-0.89]; p=0.001) |
| Objective Response Rate (ORR) | 53.1% (WELIREG + Lenvatinib) vs 40.2% (Cabozantinib) |
| Duration of Response (DOR) | 22.0 months (WELIREG + Lenvatinib) vs 11.9 months (Cabozantinib) |
| Prior Line of Therapy | Following anti-PD-1 or PD-L1 inhibitor |
| US Approval Date | September 2026 |
| Conference Presentations | American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, European Society for Medical Oncology (ESMO) Congress 2026 |
Merck's WELIREG Plus Lenvatinib Receives Positive EU CHMP Opinion for Advanced ccRCC
Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of WELIREG (belzutifan) plus lenvatinib for adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) whose disease progressed after a PD-1 or PD-L1 inhibitor. This recommendation, based on positive progression-free survival (PFS) results from the Phase 3 LITESPARK-011 trial, showed a 26% reduction in the risk of disease progression or death (HR=0.74; p=0.001) compared to cabozantinib. If approved by the European Commission, this regimen would be the first and only approved combination of a HIF-2α inhibitor and a multi-targeted VEGFR-TKI in the European Union for this patient population.
- The positive CHMP opinion is a significant regulatory milestone, moving WELIREG plus lenvatinib closer to marketing authorization in the European Union, Iceland, Liechtenstein, and Norway. This potential approval would introduce a novel, first-in-class treatment option for advanced ccRCC patients who have progressed on prior anti-PD-1/PD-L1 therapy, addressing a critical unmet need in the region with a unique combination of a HIF-2α inhibitor and a multi-targeted VEGFR-TKI.
- The recommendation is strongly supported by robust efficacy data from the Phase 3 LITESPARK-011 trial. The combination demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), reducing the risk of disease progression or death by 26% (HR=0.74 [95% CI, 0.61-0.89]; p=0.001) compared to cabozantinib. Additionally, it showed a superior objective response rate (ORR) of 53.1% versus 40.2% for cabozantinib, and an improved median duration of response (DOR) of 22.0 months compared to 11.9 months.
- While overall survival (OS), the study’s other dual primary endpoint, did not meet statistical significance at the final analysis (HR=0.85), the WELIREG and lenvatinib combination had already secured U.S. Food and Drug Administration (FDA) approval in September 2026 for the same indication. This prior U.S. approval, also based on the LITESPARK-011 trial results, underscores the clinical value and regulatory recognition of the regimen despite the OS outcome in the final analysis.
Evolving Treatment Landscape for Advanced ccRCC Post-Immunotherapy
Belzutifan, a first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, has defined the post-anti-PD-1/PD-L1 evolution in advanced clear cell renal cell carcinoma (ccRCC). Belzutifan received its first FDA approval in 2021 for treating clinical manifestations of von Hippel-Lindau (VHL) disease including renal cell carcinoma (RCC) followed by approval in 2023 for treating advanced sporadic RCC that has progressed through multiple lines of treatment. In the phase III LITESPARK-005 trial, patients receiving belzutifan had significant improvement in progression-free survival (PFS) compared with everolimus (PFS rate at 12 months: 33.4% vs. 17.1%; PFS rate at 18 months: 24.0% vs. 8.3%, respectively), as well as in objective response rate compared with everolimus (22.7% vs. 3.5%, respectively). There was no significant difference in median overall survival, with 21.4 months for belzutifan and 18.1 months for everolimus (hazard ratio [HR] 0.88; p = 0.20). Earlier, in patients with ccRCC who received 120 mg once daily (n = 55) in the first-in-human phase 1 study (NCT02974738), the confirmed objective response rate was 25% (all partial responses), and the median progression-free survival was 14.5 months, with the most common grade ≥3 adverse events were anemia (27%) and hypoxia (16%).
Dose optimization and combination development have further clarified belzutifan use after prior systemic therapy including an anti-PD-(L)1 regimen. The phase II LITESPARK-013 study (NCT04489771) enrolled patients with advanced clear cell RCC whose disease progressed after one to three prior systemic therapies, including an anti-PD-(L)1 regimen, and randomly assigned 1:1 to receive belzutifan 120 or 200 mg once daily. The ORR was 23.7% versus 23.1% for the 120 mg and 200 mg groups, respectively [P = 0.5312; -0.5%, 95% confidence interval (CI) -14.0% to 12.9%]. The median DOR was not reached for the 120 mg arm and was 16.1 months (2.1+ to 23.5+) for the 200 mg arm. No between-group differences were observed for PFS [hazard ratio (HR) 0.94, 95% CI 0.63-1.40] or OS (medians not reached; HR 1.11, 95% CI 0.65-1.90), and grade 3 or 4 treatment-related adverse events were observed in 35 patients (46.1%) in the 120 mg group and 36 patients (46.2%) in the 200 mg group, further supporting 120 mg once daily as the preferred dose. Subsequently, LITESPARK-011 established belzutifan plus lenvatinib as a superior post-immunotherapy option over cabozantinib in advanced ccRCC, the first phase III superiority result in this context.
In parallel, trial data have discouraged immune checkpoint inhibitor (ICI) rechallenge after progression on prior ICI. In the phase 3 TiNivo-2 Study, patients with metastatic renal cell carcinoma who have progressed following one or two lines of therapy including one ICI were randomised 1:1 to tivozanib (0.89 mg per day, orally) plus nivolumab (480 mg every 4 weeks, intravenously) or tivozanib (1.34 mg per day, orally). Median PFS was 5.7 months (95% CI 4.0-7.4) with tivozanib-nivolumab and 7.4 months (5.6-9.2) with tivozanib monotherapy (hazard ratio 1.10, 95% CI 0.84-1.43; p = 0.49). Among those with an ICI as their immediate previous therapy (n = 244), median PFS was 7.4 months (95% CI 5.6-9.6) with tivozanib-nivolumab and 9.2 months (7.4-10.0) with tivozanib monotherapy. Recent results from CONTACT-3 and TiNivo-2 confirm that ICI rechallenge should be generally discouraged, while tivozanib monotherapy has efficacy in the post-ICI setting. Exploratory monotherapy approaches have also failed to advance the post-immunotherapy standard, as abemaciclib 200 mg twice daily in patients with advanced pretreated RCC progressing after at least 1 prior regimen including immunotherapy and a VEGFR TKI showed ORR was 0% (0/11; 8 progressive disease, 1 stable disease stopping for clinical progression, 2 not evaluable with clinical progression).
Unmet Needs in Advanced ccRCC After Immunotherapy Progression
Most patients with advanced clear cell renal cell carcinoma eventually develop disease progression after initial benefit from anti-PD-1/PD-L1-based regimens, and therapeutic options after immunotherapy progression remain limited by resistance biology and lack of validated selection tools. The field is moving from empirical regimen selection toward a model that integrates disease tempo, patient fitness, translational biomarkers, and mechanism-based sequencing.
Acquired resistance through compensatory immune and tumor-intrinsic mechanisms: Increased expression of alternative immune checkpoints including TIM3, LAG3, and PD-1 as well as increased CD8 tumor-infiltrating lymphocytes were observed in post-treatment tumor than in pre-treatment tumor of a renal cell carcinoma patient, while resistance arises through tumor-intrinsic metabolic reprogramming, impaired antigen presentation, compensatory checkpoint signaling, and stromal-myeloid exclusion within the tumor microenvironment.
Biomarker-challenged disease with limited predictive value: Renal cell carcinoma remains a biomarker-challenged disease in which PD-L1 and tumor mutational burden have limited predictive value, while PBRM1 status, VHL-driven pseudohypoxia, and spatial immune architecture are biologically informative but not yet clinically validated as stand-alone selection tools.
Intratumoral heterogeneity and immune escape confounding response: Intratumoral heterogeneity (ITH) is a hallmark of clear cell renal cell carcinoma (ccRCC) that reflects the trajectory of evolution and influences clinical prognosis, with angiogenesis, lymphocytic infiltration, and myeloid infiltration varying significantly across regions of the same patient, potentially confounding their utility as biomarkers of ICI response; elevated ITH associated with HLA LOH, CDKN2A/B loss, elevated myeloid expression, reduced peripheral T cell receptor (TCR) diversity, and putative neoantigen depletion.
Tissue sampling limitations for PD-L1 assessment: Most studies of PD-L1 are limited by evaluation in primary rather than metastatic sites, and in biopsy samples, which may not be representative.
Toxicity burden of combination approaches and survivorship effects: Compared with sunitinib, the RRs of all-grade hypertension, arthralgia, rash, proteinuria, high-grade (grades 3-5) arthralgia, and proteinuria developed after ICI and anti-VEGF combination therapy were increased, and chronic irAEs at last follow-up included hypothyroidism (10.6%), arthritis (3.2%), adrenal insufficiency (3.2%) and neuropathy (2.8%), with new diagnoses of type 2 diabetes (6.5%) and hypertension (6.0%).
Efficacy-effectiveness gap and sequencing complexity: Pivotal phase III trials have established superior survival for contemporary ICI-based regimens over sunitinib; however, cross-trial heterogeneity, differences in IMDC risk distribution, varying toxicity profiles, and selection of fitter trial populations complicate simple regimen ranking, and real-world studies confirm that outcomes in routine practice are frequently less favorable than those reported in registration studies, but these differences are partly explained by confounding related to performance status, comorbidity burden, access to care, toxicity management, and treatment sequencing.
LITESPARK-011: Efficacy and Safety of Belzutifan + Lenvatinib
Recent studies in advanced renal cell carcinoma with a clear cell component following anti-PD-1/PD-L1 therapy include the phase 3 TiNivo-2 Study and a phase I/II study of telaglenastat in combination with nivolumab. Both studies enrolled patients with progression after prior checkpoint inhibitor therapy and reported objective response and progression-free survival with tolerability data.
| Study | Intervention | Key Efficacy Outcomes | Key Safety Outcomes |
|---|---|---|---|
| TiNivo-2 Study | Tivozanib plus nivolumab versus tivozanib monotherapy | Median PFS was 5.7 months (95% CI 4.0-7.4) with tivozanib-nivolumab and 7.4 months (5.6-9.2) with tivozanib monotherapy (hazard ratio 1.10, 95% CI 0.84-1.43; p=0.49) | Serious adverse events occurred in 54 (32%) of 168 patients receiving tivozanib-nivolumab and 64 (37%) of 171 patients receiving tivozanib monotherapy. One (<1%) treatment-related death occurred (tivozanib group) |
| Phase I/II study of telaglenastat (CB-839) in combination with nivolumab | Telaglenastat combined with nivolumab | ORR was 5.9% in 17 patients with ccRCC after nivolumab, 0% in 9 patients with ccRCC after other prior anti-PD-1/PD-L1 | Most frequently reported adverse events were fatigue (42.4%; n = 50), nausea (39%; n = 46), and photophobia (32.2%; n = 38) |
Frequently Asked Questions
References
- [1] Park J, Arshad H et al.. Belzutifan in Von Hippel-Lindau Syndrome and Renal Cell Carcinoma: Mechanisms, Clinical Evidence, and Future Directions. Cureus. 2026 May. 42306392
- [2] Flippot R, Escudier B et al.. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma. Drugs. 2018 Sep. 30187355
- [3] Albiges L, Schmidinger M et al.. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma. Future oncology (London, England). 2022 Mar. 34911359
- [4] Studentova H, Rusarova N et al.. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature. Current oncology (Toronto, Ont.). 2022 Aug 3. 36005171
- [5] Bedke J, Albiges L et al.. 2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma. European urology. 2022 Feb. 34920897
- [6] Maynard MA, Evans AJ et al.. Dominant-negative HIF-3 alpha 4 suppresses VHL-null renal cell carcinoma progression. Cell cycle (Georgetown, Tex.). 2007 Nov 15. 17998805
- [7] Patrinely JR Jr, Young AC et al.. Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. European journal of cancer (Oxford, England : 1990). 2020 Aug. 32599411
- [8] Al Abbas M, Zarka J et al.. Clinical outcomes of HIF-2α inhibition in Von Hippel-Lindau disease: a multicenter real-world study. The oncologist. 2026 Sep 9. 42610708
- [9] Nuytemans L, Sys G et al.. NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma - a case report and review of the literature. Acta clinica Belgica. 2021 Apr. 31635553
- [10] Srinivasan R, Iliopoulos O et al.. Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. The Lancet. Oncology. 2025 May. 40228516
- [11] Hilser T, Darr C et al.. Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project. Cancers. 2024 Aug 28. 39272856
- [12] Chan KH, Li N et al.. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation. Journal of investigative medicine high impact case reports. 2024 Jan-Dec. 38344974
- [13] Chintalapudi MR, Markiewicz M et al.. Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL-mutant renal carcinoma cells. Carcinogenesis. 2008 Apr. 18212329
- [14] Golkaram M, Kuo F et al.. Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape. Genome medicine. 2022 Dec 19. 36536472
- [15] Aimono Y, Ogawa T et al.. [Side Effect Management in the Early Stages of Cabozantinib Administration]. Gan to kagaku ryoho. Cancer & chemotherapy. 2021 Oct. 34657061
- [16] Yoo SH, Yun J et al.. Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues. Cancer immunology, immunotherapy : CII. 2021 Jun. 33389015
- [17] Deeks ED. Belzutifan: First Approval. Drugs. 2021 Nov. 34613603
- [18] Peng L, Liang J et al.. A DNA Damage Repair Gene Signature Associated With Immunotherapy Response and Clinical Prognosis in Clear Cell Renal Cell Carcinoma. Frontiers in genetics. 2022. 35656315
- [19] Kornakiewicz A, Czarnecka AM et al.. Effect of Everolimus on Heterogenous Renal Cancer Cells Populations Including Renal Cancer Stem Cells. Stem cell reviews and reports. 2018 Jun. 29508215
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com















